Amaç: Bu çalışmanın amacı, genel pediatri servisinde kullanılan pediatrik dozaj formu olmayan (PDFO) ilaçların saptanmasıdır. Gereç ve Yöntemler: Retrospektif, tanımlayıcı nitelikteki bu çalışma, bir üniversite hastanesinin genel pediatri servisinde son 6 ayda ilaç tedavi almış olan 12 yaş altı hastaların arşiv belgelerindeki ilaç tedavilerinin incelenmesi ile gerçekleştirilmiştir. Bulgular: Çalışmaya dâhil edilen 238 hastanın yaş medyanı [çeyrekler arası aralık (ÇAA)] 2 yıl (1- 6) olup, hastaların 130'unu (%54,6) kız çocuklar oluşturmaktadır. Hastalarda en sık görülen tanılar; diabetes mellitus (%10), üst solunum yolu enfeksiyonları (%8,4) ve pnömonidir (%6,9). Hastaların 96'sında (%40,3) PDFO ilaç kullanımı tespit edilmiştir. Hastaların kullandığı toplam 729 ilacın 106'sı (%14,5) PDFO ilaç olarak nitelendirilmiştir. PDFO ilaçlar arasında en sık kullanılan etken maddeler sırasıyla allopürinol (%6,3), kaptopril (%5), fenobarbital (%5), furosemid (%4,2) ve azatiyoprindir (%4,2). PDFO ilaçlar, en sık kardiyovasküler sistem (%26), sindirim sistemi (%23) ve sinir sistemi (%16) ilaçları şeklinde dağılım göstermiştir. PDFO ilaçların %57'si 0-2 yaş, %24'ü 3-6 yaş, %19'u 7-12 yaş gruplarında kullanılmıştır. PDFO ilaçların bu yaş gruplarındaki hastalar arasında dağılımında istatistiksel olarak anlamlı bir fark görülmemiştir (p>0,05). Sonuç: Genel pediatri servisinde yatan hastalarda PDFO ilaçların yaygın olarak kullanıldığı görülmüştür. Özellikle kardiyovasküler sistem grubundaki ilaçlar, sıklıkla dozaj formları manipüle edilerek kullanılan ilaçlardır. Pediatrik ilaç tedavisinin güvenliğini artırmak amacıyla ilaçların manipülasyonu için kanıta dayalı kılavuzlar gereklidir.
Anahtar Kelimeler: Pediatri; yatan hastalar; dozaj formları
Objective: The aim of this study is to determine the nonpediatric dosage form (NPDF) of medications used in the general pediatric service. Material and Methods: This retrospective, descriptive study was carried out by examining the archive documents of patients under the age of 12 who had received medication therapy in the last 6 months in the general pediatric service of a university hospital. Results: The median age [interquartile range (IQR)] of the 238 patients included in the study was 2 years (1-6), and 130 (54.6%) of them were female. The most common diagnoses in patients are diabetes mellitus (10%), upper respiratory tract infections (8.4%) and pneumonia (6.9%), NPDF medications use was detected in 96 (40.3%) of the patients. Out of a total of 729 medications used by the patients, 106 (14.5%) were classified as NPDF medications. The most commonly used active ingredients among NPDF medications are allopurinol (6.3%), captopril (5%), phenobarbital (5%), furosemide (4.2%) and azathioprine (4.2%). NPDF medications were most frequently included in the cardiovascular system (26%), the digestive system (23%) and the nervous system (16%). Of the NPDF drugs, 57% were used in the 0-2 age group, 24% in the 3- 6 age group, and 19% in the 7-12 age group. There was no statistically significant difference in the distribution of NPDF drugs among patients in these age groups (p>0.05). Conclusion: It has been observed that NPDF medications are widely used in patients hospitalized in the general pediatric service. Especially the medications in the cardiovascular system group are drugs that are often used by manipulating their dosage forms. Evidence-based guidelines for the manipulation of medications are needed to improve the safety of pediatric medication therapy.
Keywords: Pediatric; inpatients; dosage forms
- Nahata MC, Allen LV Jr. Extemporaneous drug formulations. Clin Ther. 2008;30(11):2112-9. [Crossref] [PubMed]
- Chappell F. Medication adherence in children remains a challenge. Prescriber. 2015;26(12):31-4. [Crossref]
- Gardiner P, Dvorkin L. Promoting medication adherence in children. Am Fam Physician. 2006;74(5):793-8. [PubMed]
- Zahn J, Hoerning A, Trollmann R, Rascher W, Neubert A. Erratum: Zahn et al. Manipulation of medicinal products for oral administration to paediatric patients at a german university hospital: an observational study. Pharmaceutics 2020, 12, 583. Pharmaceutics. 2021;13(7):939. [Crossref] [PubMed] [PMC]
- Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;134(2):361-72. [Crossref] [PubMed]
- Bjerknes K, Bøyum S, Kristensen S, Brustugun J, Wang S. Manipulating tablets and capsules given to hospitalised children in Norway is common practice. Acta Paediatr. 2017;106(3):503-8. [Crossref] [PubMed]
- van der Vossen AC, Al-Hassany L, Buljac S, Brugma JD, Vulto AG, Hanff LM. Manipulation of oral medication for children by parents and nurses occurs frequently and is often not supported by instructions. Acta Paediatr. 2019;108(8):1475-81. [Crossref] [PubMed]
- Richey RH, Shah UU, Peak M, Craig JV, Ford JL, Barker CE, et al. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr. 2013;13:81. [Crossref] [PubMed] [PMC]
- Gracia-Vásquez SL, González-Barranco P, Camacho-Mora IA, González-Santiago O, Vázquez-Rodríguez SA. Medications that should not be crushed. Med Univ. 2017;19(75):50-63. [Crossref]
- Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL. Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol. 2007;59(8):1043-55. [Crossref] [PubMed]
- Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37-45. [Crossref] [PubMed]
- Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, et al. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol. 2006;62(11):947-52. [Crossref] [PubMed]
- Balakrishnan K, Tordoff J, Norris P, Reith D. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002. Br J Clin Pharmacol. 2007;63(1):85-91. [Crossref] [PubMed] [PMC]
- van Riet-Nales DA, de Jager KE, Schobben AF, Egberts TC, Rademaker CM. The availability and age-appropriateness of medicines authorized for children in The Netherlands. Br J Clin Pharmacol. 2011;72(3):465-73. [Crossref] [PubMed] [PMC]
- Chui J, Tordoff J, Kennedy J, Reith D. Trends in accessibility to medicines for children in New Zealand: 1998-2002. Br J Clin Pharmacol. 2004;57(3):322-7. [Crossref] [PubMed] [PMC]
- Chui J, Tordoff J, Reith D. Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol. 2005;59(6):736-42. [Crossref] [PubMed] [PMC]
- Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552-8. [Crossref] [PubMed]
- Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161(3):282-90. [Crossref] [PubMed]
- Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25(1):1-5. [Crossref] [PubMed]
.: Process List